Today, 90% of non-controlled substance medications are e-prescribed, while only 14% of controlled substance medications, including prescription opioids, are e-prescribed. This means that 86% of controlled substance prescriptions are still hand-written on a piece of paper and handed to a patient.
This is a problem.
Between 3% and 9% of drugs that are diverted for abuse are tied to fraud and/or forgery of paper prescriptions. This is a blind spot we can no longer live with.
The rise of a full-scale epidemic
More people than ever are dying of opioid overdose and the latest figures show that opioid addiction rates continue to rise, even among older Americans. Since 1999, deaths from prescription painkiller overdose have quadrupled. And in 2015 alone, opioid overdoses killed more than 33,000 Americans. Beyond the devastating loss of life, prescription opioid abuse costs the United States $55 billion in health and social costs each year, according to a 2011 study by Birnbaum, et al.
The crisis was recently declared a public health emergency by President Trump to provide additional resources to combat it with greater urgency.
Taking paper out of the game
Paper prescriptions are not only prone to inaccuracy and quality issues, they’re also vulnerable to theft and forgery. One way to make certain the right person is getting the right medication is to replace paper prescriptions with electronic ones.
E-Prescribing of Controlled Substances (EPCS) provides both security and convenience from the point of prescribing to the pharmacy dispensing medications to the patient. Keeping paper prescriptions and doctors’ credentials out of the hands of dealers and people suffering from addiction will save lives.
In addition to e-prescribing, other digital tools can help address fraud and abuse by providing clinicians with a more complete and timely picture of their patients’ clinical and medication histories. The technology exists today to
- Give healthcare providers a patient’s prescription and visit history to identify potential doctor shopping.
- Ensure that only those who are authorized to prescribe controlled substances are able to do so.
- Help patients receive and adhere to their medications, and
- Inform providers if a patient was recently treated for a drug overdose.
We do not have a technology issue. We have a utilization issue.
Change is coming
The Surescripts network is taking action to fight the opioid epidemic, resulting in increased EPCS and Medication History utilization and enablement.
In 2016, there were 1.08 billion requests from providers for their patients’ medication history data and there were more than 45 million EPCS transactions (a 256% increase over 2015). EPCS enablement among prescribers nearly tripled from 5.7% in 2015 to 14.1%, and pharmacy enablement increased nearly 10% from 80.6% in 2015 to 90.3% in 2016.
Mandates are helping
Policymakers are taking action to drive nationwide adoption of EPCS and to stop opioids from ending up in the wrong hands. Several states, including New York, Maine, Virginia, Connecticut, North Carolina, and Rhode Island, have passed legislation to mandate EPCS. Now, these states have a much more secure process either in place or in the works.
State regulations, like New York’s i-STOP law, made an immediate and significant impact on driving adoption and utilization among prescribers. In 2016, the year the legislation was enacted,
- Prescriber enablement in the state increased by 45.5% (with 72% of prescribers enabled).
- Pharmacy enablement in the state increased 7% (with 98% of pharmacies enabled).
The portion of controlled substances prescribed electronically increased 54.2% (with 91% prescribed electronically) according to Surescripts 2016 National Progress Report, a summary of the network and the industry’s progress in using health IT to improve healthcare.
And at the federal level, the Every Prescription Conveyed Securely (EPCS) Act was recently introduced in the House of Representatives that would require that all controlled substances under Medicare Part D be prescribed electronically by 2020.
Where we (all can) come in
With the right technologies at our disposal today, we have the opportunity and the responsibility to fight the opioid epidemic. These tools deliver the right data to the right place at the right time and empower both clinicians and pharmacists to make informed decisions and deliver safe, affordable, and high-quality care.
But to truly unlock the full potential of these tools, we have to appreciate the “network effect”, which means that only as allies coming together from every facet of the healthcare system will we be able to affect positive change when it comes to opioid abuse.
For our part, we’re using the network alliance we built 17 years ago to replace paper prescriptions with electronic ones in order to answer some of the most pressing questions that healthcare professionals ask when making care decisions about their patients, like:
- What medication is my patient taking?
- What is my patient’s clinical history?
- Is my patient adhering to their medication therapies or taking a medication inappropriately?
- Has my patient received care or medications from other providers?
The answers to these everyday questions are relevant to the opioids conversation because the information conveyed is critical to preventing fraud, addiction, overdose, and death. It’s not the singular solution to the whole problem of opioid abuse in the U.S., but it puts the technology solutions we have in our hands today on the front lines, where they can do the most good.
Paul Uhrig is the Chief Adminstrative, Legal & Privacy Officer for Surescripts. He is responsible for a number of critical corporate functions, including internal audit, legal, privacy, security, policy, compliance, and government affairs.
Mr. Uhrig came to Surescripts from the law firm of Gardner Carton & Douglas LLP in Washington, D.C., where he was vice chairman of the firm's corporate department, chairman of the corporate department's regulated industries transactions practice group, and a member of the firm's health department. Prior to joining Surescripts, Mr. Uhrig represented Surescripts as its outside general counsel since its inception.
Mr. Uhrig brings 25 years of experience to Surescripts, focusing on the healthcare industry throughout that time. At Gardner Carton & Douglas, Mr. Uhrig focused on mergers, asset and stock acquisitions, joint venture formation and corporate planning with healthcare clients. His clients included private equity investors in middle market transactions, portfolio companies, healthcare systems, ancillary providers of healthcare services, physician groups, and investors involved with health industry projects and various other enterprises related to the healthcare industry.
Mr. Uhrig received his law degree from the American University, Washington College of Law, and his Bachelors of Arts in Economics from The University of Notre Dame.